Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $12 million versus the consensus estimate of $11.67 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.